Abstract 1844: A CD70 antibody-drug conjugate is highly active and induces long term remission in patient-derived xenograft mouse models of cutaneous T cell lymphoma

Chi-Heng Wu(National Taiwan University), Weiyun Z. Ai(City College of San Francisco), Ryan M. Gill(University of California, San Francisco), Frank McCormick(Frederick National Laboratory for Cancer Research), Linlin Wang(University of California, San Francisco), Chen‐Yen Yang(University of California, San Francisco)
Cancer Research
July 1, 2021
10.1158/1538-7445.am2021-1844
Cited by 0

Related Papers

Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target
|Cancer Cell|2013|571
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428